Wanda Y Wu1, David W Biery2, Adam N Berman2, Grace Hsieh3, Sanjay Divakaran2, Sumit Gupta4, Michael L Steigner4, Ayaz Aghayev4, Hicham Skali2, Donna M Polk2, Jorge Plutzky2, Christopher P Cannon2, Marcelo F Di Carli3, Ron Blankstein5. 1. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Boston University School of Medicine, Boston, MA, USA. 2. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: rblankstein@bwh.harvard.edu.
Abstract
BACKGROUND: Coronary artery calcium (CAC) scoring can identify individuals who may benefit from aggressive prevention therapies. However, there is a paucity of contemporary data on the impact of CAC testing on patient management. METHODS: Retrospective cohort study of adults who underwent CAC testing at Brigham and Women's Hospital between 2015 and 2019. Information on baseline medications, follow-up medications, lifestyle modification, and downstream cardiovascular testing within one-year post-CAC were obtained from electronic health records. RESULTS: Of the 839 patients with available baseline and follow-up data, 376 (45%) had a CAC = 0, 289 (34%) had CAC = 1-99, and 174 (21%) had CAC≥100. The mean age at time of CAC testing was 59 ± 9.7 years. Patients with higher CAC scores were more likely to be male, have diabetes and hypertension, and have higher low-density lipoprotein cholesterol and lower high-density lipoprotein cholesterol. A non-zero CAC score was associated with initiation of aspirin (41% increase, p < 0.001), anti-hypertensives (9% increase, p = 0.031), and lipid-lowering therapies (114% increase, p < 0.001), whereas CAC = 0 was not. Among individuals with CAC≥100, 75% were started on new or more intense lipid-lowering therapy. Higher calcium scores correlated with increased physician recommendations for diet (p = 0.008) and exercise (p = 0.004). The proportion of cardiovascular downstream testing following CAC was 9.1%, and the majority of patients who underwent additional testing post-CAC had CAC scores ≥100. CONCLUSION: Approximately half of individuals referred for CAC testing had evidence of calcified coronary plaque, and of those who had significant calcifications (CAC≥100), nearly 90% were prescribed lipid-lowering therapies post-CAC. Rates of downstream non-invasive testing were low and such testing was mostly performed in patients who had at least moderate CAC.
BACKGROUND: Coronary artery calcium (CAC) scoring can identify individuals who may benefit from aggressive prevention therapies. However, there is a paucity of contemporary data on the impact of CAC testing on patient management. METHODS: Retrospective cohort study of adults who underwent CAC testing at Brigham and Women's Hospital between 2015 and 2019. Information on baseline medications, follow-up medications, lifestyle modification, and downstream cardiovascular testing within one-year post-CAC were obtained from electronic health records. RESULTS: Of the 839 patients with available baseline and follow-up data, 376 (45%) had a CAC = 0, 289 (34%) had CAC = 1-99, and 174 (21%) had CAC≥100. The mean age at time of CAC testing was 59 ± 9.7 years. Patients with higher CAC scores were more likely to be male, have diabetes and hypertension, and have higher low-density lipoprotein cholesterol and lower high-density lipoprotein cholesterol. A non-zero CAC score was associated with initiation of aspirin (41% increase, p < 0.001), anti-hypertensives (9% increase, p = 0.031), and lipid-lowering therapies (114% increase, p < 0.001), whereas CAC = 0 was not. Among individuals with CAC≥100, 75% were started on new or more intense lipid-lowering therapy. Higher calcium scores correlated with increased physician recommendations for diet (p = 0.008) and exercise (p = 0.004). The proportion of cardiovascular downstream testing following CAC was 9.1%, and the majority of patients who underwent additional testing post-CAC had CAC scores ≥100. CONCLUSION: Approximately half of individuals referred for CAC testing had evidence of calcified coronary plaque, and of those who had significant calcifications (CAC≥100), nearly 90% were prescribed lipid-lowering therapies post-CAC. Rates of downstream non-invasive testing were low and such testing was mostly performed in patients who had at least moderate CAC.
Authors: Carl E Orringer; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Ronald B Goldberg; Edward A Gill; Kevin C Maki; Laxmi Mehta; Terry A Jacobson Journal: J Clin Lipidol Date: 2020-12-11 Impact factor: 4.766
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: Circulation Date: 2018-11-10 Impact factor: 29.690
Authors: Ankur Gupta; Emily Lau; Ravi Varshney; Edward A Hulten; Michael Cheezum; Marcio S Bittencourt; Michael J Blaha; Nathan D Wong; Roger S Blumenthal; Matthew J Budoff; Craig A Umscheid; Khurram Nasir; Ron Blankstein Journal: JACC Cardiovasc Imaging Date: 2017-08
Authors: Alan Rozanski; Heidi Gransar; Leslee J Shaw; Johanna Kim; Lisa Miranda-Peats; Nathan D Wong; Jamal S Rana; Raza Orakzai; Sean W Hayes; John D Friedman; Louise E J Thomson; Donna Polk; James Min; Matthew J Budoff; Daniel S Berman Journal: J Am Coll Cardiol Date: 2011-04-12 Impact factor: 24.094
Authors: Stefan M Nidorf; Aernoud T L Fiolet; Arend Mosterd; John W Eikelboom; Astrid Schut; Tjerk S J Opstal; Salem H K The; Xiao-Fang Xu; Mark A Ireland; Timo Lenderink; Donald Latchem; Pieter Hoogslag; Anastazia Jerzewski; Peter Nierop; Alan Whelan; Randall Hendriks; Henk Swart; Jeroen Schaap; Aaf F M Kuijper; Maarten W J van Hessen; Pradyot Saklani; Isabel Tan; Angus G Thompson; Allison Morton; Chris Judkins; Willem A Bax; Maurits Dirksen; Marco Alings; Graeme J Hankey; Charley A Budgeon; Jan G P Tijssen; Jan H Cornel; Peter L Thompson Journal: N Engl J Med Date: 2020-08-31 Impact factor: 91.245
Authors: Raza H Orakzai; Khurram Nasir; Sarwar H Orakzai; Nove Kalia; Ambarish Gopal; Kiran Musunuru; Roger S Blumenthal; Mathew J Budoff Journal: Am J Cardiol Date: 2008-01-28 Impact factor: 2.778
Authors: David J Maron; Judith S Hochman; Harmony R Reynolds; Sripal Bangalore; Sean M O'Brien; William E Boden; Bernard R Chaitman; Roxy Senior; Jose López-Sendón; Karen P Alexander; Renato D Lopes; Leslee J Shaw; Jeffrey S Berger; Jonathan D Newman; Mandeep S Sidhu; Shaun G Goodman; Witold Ruzyllo; Gilbert Gosselin; Aldo P Maggioni; Harvey D White; Balram Bhargava; James K Min; G B John Mancini; Daniel S Berman; Michael H Picard; Raymond Y Kwong; Ziad A Ali; Daniel B Mark; John A Spertus; Mangalath N Krishnan; Ahmed Elghamaz; Nagaraja Moorthy; Whady A Hueb; Marcin Demkow; Kreton Mavromatis; Olga Bockeria; Jesus Peteiro; Todd D Miller; Hanna Szwed; Rolf Doerr; Matyas Keltai; Joseph B Selvanayagam; P Gabriel Steg; Claes Held; Shun Kohsaka; Stavroula Mavromichalis; Ruth Kirby; Neal O Jeffries; Frank E Harrell; Frank W Rockhold; Samuel Broderick; T Bruce Ferguson; David O Williams; Robert A Harrington; Gregg W Stone; Yves Rosenberg Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: Matthew J Budoff; Rebekah Young; Gregory Burke; J Jeffrey Carr; Robert C Detrano; Aaron R Folsom; Richard Kronmal; Joao A C Lima; Kiang J Liu; Robyn L McClelland; Erin Michos; Wendy S Post; Steven Shea; Karol E Watson; Nathan D Wong Journal: Eur Heart J Date: 2018-07-01 Impact factor: 35.855